# Skybound Medtech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/skybound-medtech

- Industry: Healthcare IT
- Headquarters: Houston, US
- Website: www.skyboundmedtech.com/
- Total disclosed funding: $1.3M
- Latest round: Seed (Jun 8, 2026)
- Investors on record: 1

## About

Skybound Medtech, Inc. is a US-based company focused on developing innovative medical technologies that enhance human physiology in space and tackle critical health issues on Earth. Founded in 2025 by Matthew T. Kuhn (CEO) and headquartered in Houston, US, Skybound Medtech, Inc. specializes in medical technologies that address health challenges related to space travel. In June 2026, Skybound Medtech, Inc. raised USD 1.25 million in seed funding from new investor Capital Factory. Skybound Medtech specializes in developing transformative platform medical technologies aimed at sustaining human physiology in space and addressing significant health challenges on Earth. Their core offerings focus on counteracting the adverse physiological effects experienced by astronauts during extended space missions, including musculoskeletal degradation, immune dysregulation, and radiation-induced genomic injuries. These technologies are designed to enhance bone density, muscle mass, and overall physiological durability, ultimately enabling long-duration human presence in Low Earth Orbit and beyond. Skybound's innovations target various customer bases, including space agencies, military organizations, and healthcare providers, with potential applications in lunar bases, Martian colonies, and terrestrial medicine. The company aims to reach global markets, specifically targeting the United States, Europe, and regions involved in space exploration initiatives.Skybound Medtech's revenue generation model is centered on B2B partnerships with space agencies, military entities, and healthcare institutions, focusing on the commercialization of advanced healthcare technologies. The company engages in direct transactions with these clients, typically involving customized solutions tailored to specific physiological challenges posed by prolonged exposure to microgravity and other environmental stressors. Pricing structures for these services are based on contracts that may include subscriptions for ongoing support and software updates, as well as one-time fees for the deployment of flagship technologies. As Skybound's portfolio evolves, the firm anticipates establishing long-term relationships with various stakeholders, enhancing its revenue potential through strategic collaborations and continued innovation in both space and terrestrial applications.In July 2026, Skybound Medtech, Inc. raised USD 1.25 million in Seed funding from unspecified investors. The company plans to utilize this funding to develop space-medicine devices aimed at mitigating bone loss, muscle atrophy, and enhancing trauma care. Looking ahead, Skybound aims to launch new products designed for health challenges associated with long-duration space missions and expand its market reach into the United States and Europe by 2027.

## Funding rounds

- Seed, Jun 8, 2026, $1.3M — Capital Factory

## Investors

- Capital Factory (https://capitalatlas.ai/funds/capital-factory) — Seed